Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ Tumor-infiltrating Lymphocytes (TILS001 Trial)

NCT05451784 is registered in ClinicalTrials.gov with Fundacio Clinic Barcelona as lead sponsor.

NCT NCT05451784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05451784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ Tumor-infiltrating Lymphocytes (TILS001 Trial)
Lead sponsor
Fundacio Clinic Barcelona
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 20, 2022
Completion date
September 30, 2027
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple-negative breast carcinoma